Rhythm Pharmaceuticals Inc (RYTM): Next-Year EPS Estimate 75.44%
As of 2026-07-17, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 75.44%. Featured in our EPS revision report on 2026-06-24.
On 2026-07-15, analyst consensus for RYTM's next-year EPS growth shifted from 76.47% to 75.44% — a negative change of 1.03 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at -0.77%.
What's Driving This
The primary driver for RYTM’s rise was an analyst upgrade on July 7, 2026, raising next-year EPS growth estimates by 1.10 percentage points. This revision was supported by positive interim Phase 2 data for setmelanotide in Prader-Willi syndrome and new data in acquired hypothalamic obesity and Bardet-Biedl syndrome presented at ENDO
Generated 2026-07-16 from news as of 2026-07-16
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 75.44%
- EPS growth this year
- -0.77%
- EPS next quarter (est)
- -$0.81
- Last price
- $106.60
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-17 | 75.44% | -0.77% | -$0.81 | $106.60 |
| 2026-07-16 | 75.44% | -0.77% | -$0.81 | $106.09 |
| 2026-07-15 | 75.44% | -0.77% | -$0.81 | $109.69 |
| 2026-07-14 | 76.47% | -0.89% | -$0.81 | $109.96 |
| 2026-07-13 | 76.54% | -1.19% | -$0.81 | $107.49 |
| 2026-07-12 | 76.54% | -1.19% | -$0.81 | $108.40 |
| 2026-07-09 | 76.54% | -1.19% | -$0.81 | $115.48 |
| 2026-07-08 | 76.90% | -1.19% | -$0.81 | $114.43 |
| 2026-07-07 | 76.90% | -1.19% | -$0.81 | $114.46 |
| 2026-07-06 | 75.80% | -1.25% | -$0.81 | $111.68 |
| 2026-07-05 | 75.80% | -1.25% | -$0.81 | $114.17 |
| 2026-07-02 | 75.80% | -1.25% | -$0.81 | $114.17 |
| 2026-07-01 | 75.80% | -1.25% | -$0.81 | $110.41 |
| 2026-06-30 | 75.80% | -1.25% | -$0.81 | $111.03 |
| 2026-06-29 | 75.80% | -1.25% | -$0.81 | $110.04 |
| 2026-06-28 | 75.80% | -1.25% | -$0.81 | $109.84 |
| 2026-06-25 | 75.80% | -1.25% | -$0.81 | $108.26 |
| 2026-06-24 | 75.80% | -1.25% | -$0.81 | $107.55 |
| 2026-06-23 | 75.80% | -1.25% | -$0.81 | $106.19 |
| 2026-06-22 | 76.69% | -0.55% | -$0.81 | $101.39 |
| 2026-06-21 | 76.69% | -0.55% | -$0.81 | $96.79 |
| 2026-06-18 | 76.69% | -0.55% | -$0.81 | $96.79 |
| 2026-06-17 | 76.69% | -0.55% | -$0.81 | $95.83 |
| 2026-06-16 | 76.69% | -0.55% | -$0.81 | $89.72 |
| 2026-06-15 | 76.69% | -0.55% | -$0.81 | $89.70 |
| 2026-06-14 | 76.52% | -1.25% | -$0.81 | $88.38 |
| 2026-06-11 | 76.52% | -1.25% | -$0.81 | $87.66 |
| 2026-06-10 | 76.52% | -1.25% | -$0.81 | $85.71 |
| 2026-06-09 | 76.52% | -1.25% | -$0.81 | $87.86 |
| 2026-06-08 | 76.52% | -1.25% | -$0.81 | $85.93 |
Reports Featuring RYTM
Recent News
- Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- The Battle Against Genetic Obesity Just Sent This Biotech Stock FlyingInvestor's Business Daily
- Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeGlobeNewswire
- Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine SocietyGlobeNewswire
Screen Performance
Aggregate stats across all 1864 tickers our top-EPS-revision screen has flagged over the past 107 days.
- Median return since detection
- +2.5%
- % of tickers in the green
- 55%
- Median return on winners
- +20.8%
- Large revisions captured
- 1048
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-07-17, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 75.44%, based on analyst consensus.
When was the latest EPS estimate revision for RYTM?▾
The most recent revision occurred on 2026-07-15, when analysts adjusted the next-year EPS growth estimate from 76.47% to 75.44%.
What sector and industry does Rhythm Pharmaceuticals Inc belong to?▾
Rhythm Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RYTM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Rhythm Pharmaceuticals Inc (RYTM) appears here because it was detected by our daily top-EPS-revision-performer screen.